Amelioration of the β-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments

Diabetes/Metabolism Research and Reviews

Volumn 20, Issue 3, 2004, Pages 211-218

  Takatori, Atsushi ^a   Ishii, Yoshiyuki ^a   Itagaki, Shin Ichi ^a   Kyuwa, Shigeru ^a   Yoshikawa, Yasuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

AGE inhibitor; Antioxidant; APA hamsters; Diabetes mellitus; Pancreatic islets

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALBUMINOID; AMINOGUANIDINE; ANTIBODY; ANTIOXIDANT; BROXURIDINE; GLUCOSE; GROWTH FACTOR; INSULIN; MALONALDEHYDE; PROTEIN INGAP; PROTEIN REG; PYRIDOXAMINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HAMSTER; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STAINING; STREPTOZOCIN DIABETES;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELL DIVISION; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; MALE; OXIDATIVE STRESS; PYRIDOXAMINE; SERUM ALBUMIN;

EID: 2642570010     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.428     Document Type: Article

References (42)

1. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
2. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003; 52: 1-8.
3. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002; 45: 85-96.
4. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A 1999; 96: 10 857-10 862.
5. Ihara Y, Toyokuni S, Uchida K, et al. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 1999; 48: 927-932.
6. Hotta M, Tashiro F, Ikegami H, et al. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 1998; 188: 1445-1451.
7. Makino H, Shikata K, Hironaka K, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995; 48: 517-526.
8. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245: 243-250.
9. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527-537.
10. Yoshino G, Matsushita M, Maeda E, et al. Effect of probucol on recovery from streptozotocin diabetes in rats. Horm Metab Res 1992; 24: 306-309.
11. Shimizu H, Uehara Y, Shimomura Y, Tanaka Y, Kobayashi I. Probucol attenuated hyperglycemia in multiple low-dose streptozotocin-induced diabetic mice. Life Sci 1991; 49: 1331-1338.
12. Gorogawa S, Kajimoto Y, Umayahara Y, et al. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 2002; 57: 1-10.
13. Fukuda M, Ikegami H, Kawaguchi Y, Sano T, Ogihara T. Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Biochem Biophys Res Commun 1995; 209: 953-958.
14. Uehara Y, Shimizu H, Sato N, Shimomura Y, Mori M, Kobayashi I. Probucol partially prevents development of diabetes in NOD mice. Diabetes Res 1991; 17: 131-134.
15. Han J-S, Norimatsu M, Sugawara Y, et al. Acute toxicity of streptozotocin in Syrian hamsters of the APA strain. J Toxicol Pathol 1990; 3: 189-199.
16. Takatori A, Nishida E, Inenaga T, et al. Functional and histochemical analysis on pancreatic islets of APA hamsters with SZ-induced hyperglycemia and hyperlipidemia. Exp Anim 2002; 51: 9-17.
17. Yamanouchi J, Takatori A, Itagaki S, Kawamura S, Yoshikawa Y. APA hamster model for diabetic atherosclerosis. 2. Analysis of lipids and lipoproteins. Exp Anim 2000; 49: 267-274.
18. Yamanouchi J, Sugawara Y, Itagaki S, Doi K. Ultrastructure of atheromatous lesions experimentally induced in Syrian hamsters of the APA strain. Histol Histopathol 1997; 12: 433-438.
19. Yamanouchi J, Nishida E, Itagaki S, Kawamura S, Doi K, Yoshikawa Y. Aortic atheromatous lesions developed in APA hamsters with streptozotocin induced diabetes: a new animal model for diabetic atherosclerosis. 1. Histopathological studies. Exp Anim 2000; 49: 259-266.
20. Horiuchi K, Takatori A, Inenaga T, et al. The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis. Exp Anim 2002; 51: 457-464.
21. Nishida E, Yamanouchi J, Ogata S, Doi K, Itagaki S. Modification of spontaneous renal lesion of APA hamsters by streptozotocin-induced diabetes. Int J Exp Pathol 1997; 78: 169-176.
22. Inenaga T, Nishida E, Kawamura S, Yoshikawa Y. Renal function tests on diabetes-induced and non-induced APA hamsters. Exp Anim 2002; 51: 437-445.
23. Takatori A, Ohta E, Inenaga T, et al. Protective effects of probucol treatment on pancreatic beta-cell function of SZ-induced diabetic APA hamsters. Exp Anim 2003; 52: 317-327.
24. Kaneto H, Kajimoto Y, Miyagawa J, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 1999; 48: 2398-2406.
25. Piercy V, Toseland CD, Turner NC. Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice. Metabolism 1998; 47: 1477-1480.
26. Stitt A, Gardiner TA, Anderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832.
27. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-227.
28. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
29. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev 1998; 30: 225-243.
30. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000; 275: 21 177-21 184.
31. +)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 2001; 30: 232-237.
32. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 1114-1120.
33. Terazono K, Yamamoto H, Takasawa S, et al. A novel gene activated in regenerating islets. J Biol Chem 1988; 263: 2111-2114.
34. Unno M, Yonekura H, Nakagawara K, et al. Structure, chromosomal localization, and expression of mouse reg genes, Reg I and Reg II. A novel type of Reg gene, Reg II, exists in the mouse genome. J Biol Chem 1993; 268: 15 974-15 982.
35. Narushima Y, Unno M, Nakagawara K, et al. Structure, chromosomal localization and expression of mouse genes encoding type III Reg, RegIII alpha, RegIII beta, RegIII gamma. Gene 1997; 185: 159-168.
36. Abe M, Nata K, Akiyama T, et al. Identification of a novel Reg family gene, Reg IIIdelta, and mapping of all three types of Reg family gene in a 75 kilobase mouse genomic region. Gene 2000; 246: 111-122.
37. Zenilman ME, Perfetti R, Swinson K, Magnuson T, Shuldiner AR. Pancreatic regeneration (Reg) gene expression in a rat model of islet hyperplasia. Surgery 1996; 119: 576-584.
38. Bone AJ, Banister SH, Zhang S. Islet cell defence and repair mechanisms in insulin-dependent diabetes: a role for the pancreatic regenerating (Reg) gene? Biochem Soc Trans 1994; 22: 37-41.
39. Rafaeloff R, Barlow SW, Rosenberg L, Vinik AI. Expression of Reg gene in the Syrian golden hamster pancreatic islet regeneration model. Diabetologia 1995; 38: 906-913.
40. Rafaeloff R, Pittenger GL, Barlow SW, et al. Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. J Clin Invest 1997; 99: 2100-2109.
41. Anastasi E, Ponte E, Gradini R, et al. Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. Eur J Endocrinol 1999; 141: 644-652.
42. Watanabe T, Yonemura Y, Yonekura H, et al. Pancreatic beta-cell replication and amelioration of surgical diabetes by Reg protein. Proc Natl Acad Sci U S A 1994; 91: 3589-3592.